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Abstract
Buspirone, widely used as a neuropsychiatric drug, has also shown potentials for motor function recovery of injured spinal cord.
However, the optimum dosages of such treatment remain unclear. In this study, we investigated the dose-response of Buspirone
treatment on reaching and grasping function in cervical cord injured rats. Seventeen adult Sprague-Dawley rats were trained to
reach and grasp sugar pellets before a C4 bilateral dorsal column crush injury. After 1 week post-injury, the rats were divided into
3 groups to receive 1 of 3 different dosages of Buspirone (i.p., 1 dose/day: 1.5, n ¼ 5; 2.5, n ¼ 6 and 3.5 mg/kg b.w., n ¼ 6).
Forelimb reaching and grip strength test were recorded once per week, within 1 hour of Buspirone administration for 11 weeks
post-injury. Different dose groups began to exhibit differences in reaching scores from 4 weeks post-injury. From 4-11 weeks
post-injury, the reaching scores were highest in the lowest-dose group rats compared to the other 2 dose groups rats. Average
grip strength was also found higher in the lowest-dose rats. Our results demonstrate a significant dose-dependence of Buspirone
on the recovery of forelimb motor functions after cervical cord injury with the best performance occurring at the lowest dose
tested.
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Introduction
Serotonin (5-hydroxytryptamine or 5-HT) is a monoamine neu-
rotransmitter. Almost all 5-HT axons found within the mam-
malian spinal cord supraspinally originate from the brainstem.1
Serotonin plays a vital role in modulating the activity of the
spinal network for the gain control of volitional limb move-
ments2 and inducing partial recovery of plantar stepping.3
Disruption of serotonin pathways following spinal cord injury
(SCI) results in depletion of 5-HT in the spinal neural network,
dysregulation of 5-HT transporters as well as elevated expres-
sion and sensitivity of specific 5-HT receptors below the spinal
lesion.4
These changes in the serotonergic system of the spinal cord
can produce varying degrees of functional complications after
paralysis. To date, various neuropharmacologies have been
tested to restore hindlimb functions after SCI.5-9 5-HT receptor
agonists, when combined with electrical stimulation restores
locomotor function in SCI rats primarily by neuromodulating
the physiological states of spinal networks that generate step-
ping.10,11 Although serotonin agonists have demonstrated
improved functional recovery in standing and stepping in SCI
paraplegics, limited progress has been made in improving arm
and hand functions using such neurochemical modulation.12
Moreover, 5HT2 receptor agonists alone can facilitate the
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persistent sodium inward current which increases the excitation
of motorneurons in chronic spinal cord injured rats.13 The
above findings indicate the importance of serotonin receptor
agonists in spinal cord injuries.
Buspirone, a serotonin 5-HT1A receptor partial agonist acts
as an antagonist for dopamine D2 autoreceptors. There is
some evidence of a weak affinity for 5-HT2 receptors, com-
monly used as an anxiolytic drug, and has the potential to
improve brain functions after injuries or diseases.14 In recent
studies on SCI patients, it has been suggested that electrical
stimulation of the spinal cord, when combined with regular
Buspirone administration can restore voluntary control of the
hand12 and locomotor function.15,16 Previous reports have
shown that low doses of Buspirone can stimulate the soma-
todendritic 5-HT1A receptors in an ex-vivo bovine brain
17 and
can trigger motor activity in rats.18 However, high doses of
Buspirone can block the postsynaptic terminals on dopami-
nergic neurons and induce behavioral changes.19 In Parkin-
son’s diseases, a dose of 2 mg/kg b.w. of Buspirone has also
been reported to reduce locomotor activity. Similar effects
have also been reported in other neurological disorders.20
Likewise, high doses of a 5HT2 receptor agonist may activate
5HT1A receptor agonists and modulate the interneuronal
activity to fire repetitively in chronic conditions.13 The opti-
mal dose response of Buspirone for improving arm and hand
functions in cervical SCI is unclear. The lack of clarity in the
dose-response relationships among the experiments noted
above demonstrate that to understand the efficacy of a given
dose of Buspirone, in spite of its long history of clinical use,
care must be taken to control the dosage, physiological sys-
tem, the timing of the response and the species of interest. In
the current study, we investigated the dose-responses of Bus-
pirone treatment on reaching and grasping function after a
cervical spinal cord injury in rats.
Methods
All experimental procedures were carried out according to the
guidelines and approval of the Animal Subjects Ethics Sub-
committee of The Hong Kong Polytechnic University.
Animal Subjects
Seventeen adult female Sprague-Dawley rats (230 + 20 grams
b.w.) were used in this study. Acclimation of the animals was
done for 1 week prior to the behavioral training. Adlibitum
food and water were provided before starting the forelimb
training. Body weights were monitored after the surgery
weekly. The room temperature (24C) and humidity (40%)
were carefully maintained.
Reaching and Grasping Task
All the rats were trained (thrice/week) to reach, grasp and eat
the 45 mg dustless sugar pellets (Bio-serv®, Flemington, USA)
from a pit flatform (3 cm  2 cm) of a specialized box (18 cm
 15 cm  31 cm) as described before.21,22 Food restriction
was provided before each task to master the technique. During
each test, 30 pellets were provided to grasp and eat. After 6
weeks of training, the rats demonstrated at least a 60% success
rate in their reaching and grasping task. Beginning at 1-week
post-injury, weekly reaching and grasping scores were mea-
sured for 11 weeks (Figure 1).
Grip Strength Test
Prior to the surgery, forelimb grip strength tests were con-
ducted to acclimatize the animal to the test apparatus using a
custom-made grip strength meter as described previously.23 By
holding the base of the tail, the rat was gently pulled away from
Figure 1. Experimental procedure. Seventeen Sprague-Dawley rats were trained to reach and grasp the pellets for 6 weeks. After
mastering the task, all rats received a dorsal funiculus crush injury at the C4 level and subsequent implantation of EMG electrodes in the
preferred forearm muscles (extensor digitorum and flexor digitorum). After 1 week of recovering from surgery, the rats were ranked and
divided into 3 Buspirone dosages groups: Group A, B and C; low, 1.5, n ¼ 5; medium, 2.5; n ¼ 6 and, high-dose, 3.5 mg/kg b.w., n ¼ 6;
respectively. Weekly forelimb reaching task and grip strength tests were conducted for weeks 1-6 continuously and week 9, after which the drug
was withdrawn and the rats were tested again in week 11.
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the grid which was connected to a force sensor. From 1-week
post-injury, weekly maximum grip strength was measured for
each rat (Figure 1).
Cervical Cord Injury
All surgical procedures were carried out under aseptic condi-
tions. To induce anesthesia, at first the rats were anesthetized
with 5% isoflurane gas which was maintained at 1.5-2%
throughout the surgery via a face mask. To prevent hypother-
mia, the body temperature was maintained at 37C by placing
the rat on an automated heating pad (ThermoStar Homeother-
mic Monitoring System, RWD Life Science Co. Ltd., China).
To minimize the pain, an analgesic, Buprenorphine HCl
(Buprenex®, 0.5mg/kg, s.c.) was administered before the sur-
gery. In deep anesthetic condition, an incomplete spinal cord
injury at the C4 level was carried out as described previously.24
In brief, after a 3-4 cm skin incision was made using a sharp
scalpel blade, the skin and fascia were retracted by a forceps to
reveal the muscles beneath. After retracting the paravertebral
muscles a laminectomy was performed at the C3-C4 vertebrae
to reveal the spinal cord. The tips of fine forceps were used to
crush the dorsal funiculi of the spinal cord (2 mm apart, 2 mm
depth). A thin 2-mm length of a stainless steel sterile rod was
used to ensure the consistency of the lesion size during each
surgery at the C4 level. The SCI resulted in significant loss of
supraspinal control with moderate motor and sensory impair-
ments.25,26 Saline water was used to moisturize the skin area
and the muscles were sutured by using 4.0 Vicryl sutures.
Electrode Implantation
To record the EMG signals from the preferred paw, intramus-
cular EMG electrodes were implanted into the forelimb flexor
and extensor digitorum muscles. A skin incision was made on
the skull to place a head-plug. The skin and connective tissues
were retracted from the skull. Cotton gauze was soaked and
placed on the skull to prevent dryness. Two longitudinal skin
incisions around 2 cm were carried out to place the Teflon-
coated stainless steel wires (AS631, Cooner Wire, USA) in the
flexor and extensor digitorum muscles. The fascia of the mus-
cles was retracted to reveal the belly of the desired muscle. By
using forceps the wires were then passed to the muscles
subcutaneously. A 27-gauge needle was then inserted in the
muscle belly to implant the electrode wires. After insertion, a
part of the Teflon (*0.5 mm) from the wire was removed to
make a recording electrode. The wire electrodes were then
anchored by using 4.0 Ethilon sutures and stimulation was
given through the connector to verify the position of the elec-
trode. The EMG wires were coiled to relieve the stress and the
skin incisions were closed by using 4.0 Nylon sutures. Finally,
to anchor the head-plug, 4 screws were firmly placed into the
skull after drilling and thoroughly dried. Dental cement was
then applied to immerge the screws to support the head plug
after drying.
The analgesic, Buprenorphine HCL, was administered for
3 days post-surgery. At the same time an antibiotic, Enrofloxacin
(Baytril®, 0.5mg/kg, s.c) was administered and continued twice
daily for 3 days to prevent any infection. The rats were then
moved to a temperature and humidity-controlled incubator
(AEOLUS Incubator, ICU-1801, USA) to recover from the
anesthesia. After recovering, the animals were transferred to
their individual home cages. Fresh fruit and juice were provided
for a quick recovery. The rat’s condition was monitored con-
tinuously for at least 1 week.
Drug Treatment
After recovering from the surgery at day 7, the animals’ ability
to reach and grasp the sugar pellets was tested. One of the rats
died during the recovery period from the surgery and hence one
group was slightly imbalanced. Based on the scores, the
animals were than ranked and divided into 3 balanced groups
to be administered with different dosages of Buspirone (i.p.,
1 dose/day): Group A with a low dose (1.5 mg/kg b.w.; n¼ 5),
Group B with a medium dose (2.5 mg/kg b.w.; n ¼ 6) and
Group C with a high dose (3.5 mg/kg b.w.; n ¼ 6). The drug,
Buspirone (Tocris®, UK), was previously prepared by dissol-
ving 1 mg/1 ml of ultrapure distilled water (Invitrogen®, USA).
The drug was administered intraperitoneally into different dose
groups of SCI rats up to 9 weeks post-injury. Behavior tests and
electrophysiological recordings were conducted from 0.5 to
1 hour of Buspirone administration. Each animal was video-
taped with a camera27 while retrieving food pellets. After each
forelimb reaching task and electrophysiological recording, a
grip strength test for each rat was conducted once per week,
for 9 weeks. To see the effects of the drug, after 9 weeks, the
drug administration was ceased, and the behavior tests and
electrophysiological recording were done only at week-11
post-injury. At the end of all the experiments, the rats were
euthanized with a high dose of Ketamine and Xylazine mixture
and confirmed by a surgeon according to the guideline of the
Animal Subjects Ethics Sub-Committee of The Hong Kong
Polytechnic University.
Data Acquisition and Statistical Analysis
Videotape footage of the forelimb reaching task of each rat was
examined frame by frame in windows media player to identify
the components of the grasping task. The EMG signals were
bandpass filtered at 10-1000 Hz and amplified (1,000 times) by
an analog amplifier (Model 1700 Differential AC Amplifier,
AM Systems, USA). The signals were then digitized by a data
acquisition system (Power1401-3A, Cambridge Electronics
Design Ltd., UK). The data were then visualized and recorded
on a computer for further analysis via a software interface
(Signal, Cambridge Electronics Design Ltd., UK). Based on
the synchronization of the video, extensor and flexor muscle
EMGs for every trial were plotted and calculated by a custom
script written in MATLAB (MathWorks Inc., USA). From the
EMG signals of extensor digitorum and flexor digitorum
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muscles, area-under-the curve (AUC) values were calculated as
described previously.24 The normalized AUC values for differ-
ent dose groups were then tested for statistical significance
using 2-way analysis of variance (ANOVA) followed by
Tukey’s multiple comparison post-hoc test using 2-way anal-
ysis of variance (ANOVA) followed by Tukey’s multiple com-
parison post-hoc test. Pre- and post-injury reaching scores were
compared for significance of difference by using a paired t-test.
The success rates of forelimb reaching of the 3 dose groups
were normalized to their pre-injury success rate using the fol-
lowing equation:




The scores were then evaluated for significant differences
by 2-way ANOVA. One-way ANOVA was used to analyze the
dose responses in each group. All the statistical measurements
were carried out using software (GraphPad Software Inc.,
USA) with significance levels set at p < 0.05 for all the
comparisons.
Results
A Low Dosage of Buspirone Facilitates Forelimb Reaching
and Grasping Function
Following cervical cord injury, after a few attempts the animals
could place their forelimbs on the food platform; however,
mostly failed to grasp the pellets. The post-injury forelimb
grasping success rates were compared with the pre-injury
scores. Forelimb reaching scores dropped significantly 1 week
after the cervical cord injury (68.82 + 2.33 vs. 2.05 + 1.25;
***p < 0.001, paired t-test).
All the rats were administered Buspirone, according to their
dose group, till 9 weeks post-injury and the grasping success
rate was measured. The animals started to increase their grasp-
ing function noticeably after 3 weeks post-injury. The success
rates of each dose group were compared with 1-week post-
injury scores. In Group A, significant improvements of reach-
ing function were found at weeks 4 and 5, respectively (40.33
+ 6.33 and 41.99 + 4.89, **p < 0.01, 1-way ANOVA). The
reaching score remained significantly high till week 9, and
even at week 11 after cessation of the drug treatment (respec-
tively 46.33 + 5.22 and 45.33 + 4.54;**p < 0.01, ANOVA)
(Figure 2a).
The medium-dose rats, Group B, significantly improved
their forelimb grasping function at and after 4 weeks post-
injury compared to week 1 (Figure 2b). At week 11 after the
cessation of Buspirone administration, the reaching scores
dropped but still remained significantly high compared to the
week 1 post-injury score. Group C did not exhibit any signif-
icant improvement of reaching function (Figure 2c). The aver-
age normalized reaching scores of all groups were compared
with each other (Figure 2d), showing that Group B and C
scores increased up to 3 weeks post-injury, while Group A
continued to improve up to 6 weeks. The reaching scores of
Group B rats started to decay from 5 weeks post-injury and
never recovered. At the end of the study, Group A low-dose
rats exhibited an average of 69% improvement of reaching and
grasping function over Group B and C medium- and high-dose
rats. Although the low-dose rats displayed noticeable improve-
ments in later weeks after treatment compared to the higher-
dose rats, no statistical significance was found between their
normalized reaching scores (at 11 weeks post-injury: Group A
vs. Group B, p¼ 0.8786; Group A vs. Group C, p¼ 0.6715).
Low- to Medium-Dose BUSPIRONE Treatment Improved
Distal Muscle Co-Ordination
Examples of raw EMG signals from the extensor digitorum and
flexor digitorum muscles during reaching and grasping for dif-
ferent dose groups are presented in Figure 3. At 1 week post-
injury, the amplitude and bursting properties during the sugar
pellet reaching task were relatively low compared to 9 weeks
post-injury.
The EMG signals of the extensor digitorum and flexor digi-
torum muscles were normalized for each rat to calculate the
area-under-the-curve (AUC). The normalized AUC values of
different dose groups were analyzed for statistical significance.
In each group of rats the normalized AUC of the extensor
muscle tended to increase gradually after week 6 and even after
withdrawal of the drug (Figure 4a). However, the EMG from
the flexor digitorum muscle did not show any consistent trend
over the 11 weeks of post-injury measurements, presumably in
large part due to the low number of rats, particularly for Group
C. In Group C, only 2 rats were found to have good EMG
signals and were included in Figure 4 for analysis. In the other
rats, the EMG signals were noisy and were not reliable for
analysis. In Group A, the flexor muscle activity dropped at
week 9 and dramatically increased at week 11 after withdrawal
of the drug, while in Group C the opposite phenomenon hap-
pened (Figure 4b). The medium-dose group, Group B, how-
ever, showed a similar increasing trend like the extensor
digitorum muscle. This may imply that a low- to medium-
dose of Buspirone may have more consistent effects on the
forelimb muscles on reaching and grasping function. Although
no statistically significant differences between the dose groups
were found, the similarity of the relative patterns of differences
across time in the extensor muscle and a consistently different
pattern observed in the flexor, regardless of group identity,
suggest that the dosage-time effect was different between the
extensor and flexor muscles.
Low-Dosage of Buspirone Treatment Improved Forelimb
Grip Strength
Following the forelimb reaching task, the maximum value of
the forelimb grip strength test was carried out weekly for 6
weeks and finally at week 9. After the withdrawal of Buspir-
one, the tests were carried out at week 11. The forelimb grip
strength of all 3 groups exhibited continuous improvement up
to week 4 (Figure 5).
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A similar effect of Buspirone was also found in Group B
and C. For Group B, the force was boosted from 6.67 N (weeks
1&2 post-injury) to 13.42 N (weeks 6&9 post-injury). For
Group C, the maximum grip force increased from 5.60 N
(weeks 1&2 post-injury) to 12.16 N (week 4 post-injury) and
dropped to 11.09 N at weeks 6&9 post-injury. After withdrawal
of the drug, at 11 weeks post-injury, the average grip force
increased slightly to about 11.24 N for Groups A and B. Sig-
nificantly higher grip strength (**p < 0.01 and *p < 0.05
ANOVA) in Group A, compared to Group C was found at
5 and 11 weeks post-injury (Figure 5d).
No significant relation was found between the forelimb
reaching score and the forelimb grip force in the early post-
injury weeks (data not shown). From 6 weeks of drug treat-
ment, both reaching success and grip strength values increased
in almost all the dose groups (Figure 6). Group A exhibited the
most consistent functional recovery as assessed for both fine
motor control of reaching and for gross forelimb grip strengths.
These improvements were also sustained after withdrawal of
the low dosage of the drug. The success rate and grip strength
of Group B rats increased at 6 weeks post-injury to an
optimum level, but dropped afterward. The results indicate that
each week the motor task had an influence on the functional
recovery. Unlike Group A and B rats, high-dose Group C rats
did not undergo any improvement of fine motor control. Over-
all, a higher success rate and grip strength were found for the
low-dose rats (Figure 6). The results indicate that the lowest
dose of buspirone tested provided the most consistent pattern of
functional improvements compared to the medium and high
dosages, but also suggest that maximum grip force was entirely
unrelated to performance success. It also suggests that regard-
less of group identity, the mean highest grip force occurred at
the 11th week, i.e. grip strength increased with time, but with-
out Buspirone.
Discussion
As a serotonin agonist, Buspirone, primarily known as an anxio-
lytic drug, has high affinity for 5HT1A receptors and weak affi-
nity for 5HT2A receptors. In contrast, the drug has antagonistic
properties against dopamine D2 receptors.14 A recent study has
shown the potential of the drug to improve forearm grip strength
Figure 2. Reaching and grasping scores of 3 different dose groups after Buspirone administration. a) Mean (+SEM) success rates
of Group A rats (n ¼ 30 trials/rat/test session, 5 rats). 1-week vs. 4 and 5-week post-injury scores (**p < 0.01). 1-week vs. 6, 9 and 11-week
post-injury scores (***p < 0.001). b) Mean (+SEM) success rates of Group B rats (n ¼ 30 trials/rat/test session, 6 rats). 1-week vs. 4 and
5-week post-injury scores (***p < 0.001). 1-week vs. 6 and 9-week post-injury score (**p < 0.01). 1-week vs. 11-week post-injury score
(*p < 0.05). c) No significant difference was found in the mean (+SEM) success rates of Group C (n¼ 30 trials/rat/test session, 6 rats). d) The
progression of the mean (+SEM) normalized reaching scores of all 3 groups. The dotted line is the score of a representative rat for each group.
Ahmed et al 5
function along with electric stimulation in tetraplegic patients,
but these effects do not provide strong evidence for significant
functional effects in performing daily motor tasks.12
Skilled forelimb function such as forelimb reaching and
grasping task is commonly used to examine the functional
recovery after cervical cord injury in rats.28 In a previous study,
we showed that an incremental dose of Buspirone (1 to 2 mg/kg)
can improve forelimb reaching function in rats with cervical
cord injury.29 The spontaneous recovery of forelimb function of
rats without any drug intervention was found to be less than
20% while the rats which were administered Buspirone reached
a success rate of over 60% by 6 weeks post-injury. Thus, ser-
otonergic modulation enabled over 3-fold improvements in
forelimb reaching and grasping after post-injury Buspirone
Figure 3. Raw EMG signals (n ¼ 30 trials) during forelimb reaching and grasping task at 1, 6, 9 and 11 weeks post-injury from one
representative rat (marked as a dotted line in Figure 2) from each treatment group. Only at 6 and 9 weeks post-injury was the EMG recorded
during the Buspirone administration period, while week 1 was before, and week 11 was 2 weeks after the drug treatment.
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administration. In the present study, we demonstrated that dif-
ferent dosages of Buspirone have different effects on forelimb
functional recovery after a dorsal funiculus injury in rats. Our
main finding is that the low dose (1.5 mg/kg b.w.) of Buspirone
markedly improved forelimb fine motor control and grip
strength compared to a higher dose. Furthermore, a low to
medium dose (1.5-2.5 mg/kg b.w.) of Buspirone improved the
forelimb muscle synergies of the distal muscles.
When considering the possibility of using Buspirone as a
pharmacological way to enhance the recovery of motor func-
tions, it is important to consider the dose-response characteris-
tics of other serotonergic systemic responses that have been
observed that may be detrimental or beneficial either acutely
or chronically. Based on the history of its development the dose
regimen for the treatment of behavioral effects will be of obvi-
ous importance. The effects on cerebral glucose metabolism in
response to doses ranging from 0.4 mg/kg to 40 mg/kg have
shown reduced cerebral metabolic rates for glucose in rats. A
dose of 0.4 mg/kg Buspirone can preferentially activate the
5-HT1A autoreceptors.
30 Pain sensation has been studied in rats
using dosages ranging from 0.1-2.0 mg/kg.31 Such dose can
also improve the acquisition and retention of memory in a
water maze.31 Given the distinctly dose-dependent differences
observed in the present study, each of the very few cases noted
here emphasizes the criticalness of dosage in defining its effec-
tiveness for a specific function.
From neurochemical evidence, it was found that a low
(1 mg/kg) but not high dose (5 mg/kg) of Buspirone stimulates
5-HT1A receptors and decreases striatal metabolism. The finding
also suggests that a low dose could help to release dopaminergic
neurons that could be useful in reducing Parkinsonian-like
effects.18 Furthermore, a model of L-DOPA-induced dyskinesia
in Parkinson’s disease 1 mg/kg b.w. of Buspirone did not
impair the rotarod performances in rats, while higher doses
(2 and 4 mg/kg b.w.) significantly reduced the rotarod
performance by 25% and 20%, respectively.32 A low dose of
Buspirone can significantly increase the synthesis and availabil-
ity of dopamine in the pre-synaptic terminal, whereas a higher
dose blocks postsynaptic dopaminergic receptors.19
Generally, these findings demonstrate some of the complex-
ities of Buspirone given the multiple autoreceptors in the ner-
vous system, which could contribute to the dose dependencies
of its physiological responses. The present findings suggest that
the functional window of efficacy for Buspirone, and probably
other potential pharmacological candidates with limited speci-
ficity for spinal neuromodulation, can be narrow. These data,
for example, show that the efficacy of Buspirone not only is a
function of relatively narrow ranges of dose; the timeframe
over which functional changes are likely to occur gives a clue
as to the persistence of the responses.
Other variables that need to be examined are the potential
interactive effects associated with activity-dependent mechan-
isms that might be in play. Regarding this specific interaction
of a pharmacological and activity-dependent interaction, there
have been clear examples of these 2 interventional modes hav-
ing antagonist or synergistic effects depending on whether they
were presented sequentially or simultaneously. Finally, it is
logical to assume that the highly complex serotonergic receptor
types within the spinal cord and the fact that almost all of the
serotonin is derived from supraspinal nuclei, and their axonal
projections rapidly degenerate post injury. Thus, it seems likely
that the serotonergic spinal network response to a serotonergic
acting drug will be significantly different when tested in acute
phases, as in this study, compared to the more frequently avail-
able chronic state in humans with a spinal injury. In the present
study, it was expected that the higher dose could activate the
cervical spinal network as occurs among the lumbosacral net-
works.33 The present results showed a robust effect of a low to
medium dosage effect on forelimb grasping function in the
acute phase of adaptation to the injury imposed. It appears that
Figure 4. Average area-under-the-curve (AUC) of normalized EMG signals for a) extensor digitorum and b) flexor digitorum
muscles during the single pellet reaching task in 3 different Buspirone dose groups (Group A, n ¼ 5; Group B, n ¼ 5; and Group C, n ¼ 2).
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a critical question now is, what would the dose responses be for
motor tasks in the acute vs. chronic stage of a spinal injury. We
have demonstrated previously, for example, that the efficacy of
an intervention after a spinal injury is highly dependent on the
timing at which a biochemical and an activity-dependent inter-
vention is presented.34,35
Conclusions
Buspirone had clear effects on the recovery of forelimb grasp-
ing and grip strength following administration at a dose of
1.5 mg/kg b.w. after an incomplete cervical cord injury. The
magnitude of these effects were highly dose- and post treat-
ment time-dependent. At the longest post-treatment time stud-
ied among all 3 dosage groups there was a direct relationship
between grip strength and reach and grasp success rate. How-
ever, a larger sample size and more functional tests may con-
firm the significance and synergy of the drug dosage. Based on
the EMG data represented as the total EMG activity of a pri-
mary extensor and flexor muscle per reach and grasp effort, no
clear pattern of changes was found to be closely linked to
successful performances, an issue that needs comprehensive
assessment to understand the subject-specific functional neural
reorganization adopted strategies that shaped the patterns of
recovery. From the EMG responses, it can be observed that the
low-dose rats had most consistent patterns of forelimb function
Figure 5. Maximum grip force of the 3 different dose groups after Buspirone administration. a) Mean (+SEM) maximum grip force
of Group A (n ¼ 3 trials/rat/test session, 5 rats). 2 weeks vs. 11 weeks and 9 weeks vs. 11 weeks post-injury (*p < 0.05) b) Mean (+SEM)
maximum grip force of Group B (n¼ 3 trials/rat/test session, 6 rats). No significant difference was found. c) Mean (+SEM) maximum grip force
of Group C (n ¼ 3 trials/rat/test session, 6 rats). 1 week vs. 6 weeks and 11 weeks post-injury (*p < 0.05); and 1 week vs. 9 weeks post-injury
(**p < 0.01). d) Post-injury mean (+SEM) maximum grip force of 3 dose groups. Group A showed significantly higher grip strength at week
5 (**p < 0.01) and at week 11 post-injury (*p < 0.05) compared to Group C.
Figure 6. Overall forelimb functions of each drug dose group.
Normalized success rate vs. normalized grip force at 6, 9, and
11 weeks post-injury. Data are presented as the mean (+SEM). The
marker sizes (smaller to larger) represents 6, 9 and 11 weeks post-
injury, respectively.
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compared to the medium- and high-dose rats. The two beha-
vioral motor tests and forelimb electrophysiology combined
may suggest that a low dose of Buspirone has better influence
on forelimb functional recovery than a higher dose.
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